AGF Management Ltd. Sells 213,583 Shares of Pfizer Inc. $PFE

AGF Management Ltd. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 19.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 897,580 shares of the biopharmaceutical company’s stock after selling 213,583 shares during the period. AGF Management Ltd.’s holdings in Pfizer were worth $21,757,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Pacer Advisors Inc. grew its holdings in shares of Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after purchasing an additional 17,957,928 shares in the last quarter. Amundi raised its stake in Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares in the last quarter. Nuveen LLC bought a new position in Pfizer during the first quarter valued at $389,861,000. Goldman Sachs Group Inc. grew its stake in shares of Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after buying an additional 9,041,990 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after buying an additional 4,629,976 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $24.45 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $138.99 billion, a PE ratio of 13.00, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a 50 day moving average price of $24.74 and a 200-day moving average price of $24.37. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on PFE shares. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday. Morgan Stanley lowered their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.18.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.